EGFR and prostate carcinoma: These included non-small-cell lung cancer, prostate cancer, EGFR tyrosine kinase inhibitor resistance, endocrine resistance, the relaxin signaling pathway, the FoxO signaling pathway, proteoglycans in cancer, the estrogen signaling pathway, hepatocellular carcinoma, lipids and atherosclerosis, chemical carcinogenesis—reactive oxygen species, pathways in cancer, the Ras signaling pathway, the MAPK signaling pathway, and the PI3K-Akt signaling pathway.